NCT03007693View on ClinicalTrials.gov

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ 61393215 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Healthy
Interventions
DRUG

JNJ-61393215

Participants will receive JNJ-61393215 for 7 days.

DRUG

Placebo

Participants will receive JNJ- 61393215 matching placebo for 7 days.

Trial Locations (1)

Unknown

Leiden

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03007693 - A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ 61393215 in Healthy Participants | Biotech Hunter | Biotech Hunter